Company Filing History:
Years Active: 2015-2016
Title: Innovations in Hepatitis B Treatment by TieJun Li
Introduction
TieJun Li is a prominent inventor based in Jiangsu, China, known for his significant contributions to the field of medical research, particularly in the treatment of hepatitis B. With a focus on RNA interference (RNAi) technology, he has developed innovative solutions aimed at combating this viral infection.
Latest Patents
TieJun Li holds 2 patents related to his groundbreaking work on HBV treatment. His latest patents involve RNA interference (RNAi) agents designed to treat hepatitis B infection in individuals. These patents detail the use of RNAi agents to inhibit the expression of at least one Hepatitis B virus (HBV) gene. Each agent comprises an effector sequence that is complementary to a predicted sequence transcribed from a target region. In some embodiments, the agents feature multiple effector sequences that may target the same region of an HBV gene, different regions of the same gene, or various HBV genes.
Career Highlights
TieJun Li is associated with Benitec Biopharma Limited, a company dedicated to advancing RNAi technology for therapeutic applications. His work has positioned him as a key figure in the development of innovative treatments for viral infections, particularly hepatitis B.
Collaborations
Throughout his career, TieJun Li has collaborated with notable professionals in the field, including Michael Wayne Graham and Peter French. These collaborations have further enhanced the research and development of effective treatments for hepatitis B.
Conclusion
TieJun Li's innovative work in RNA interference technology represents a significant advancement in the treatment of hepatitis B. His contributions continue to pave the way for new therapeutic options in the fight against viral infections.